Abebe Mengesha et al., J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USASafety and potency test for experimental cell culture based anti-rabies vaccine produced in EthiopiaAbebe Mengesha, Newayeselassie B, Hurrisa B, Beyene M, Denis B, Artem M, Kerga S and Urga KEthiopian Health and Nutrition Research Institute, EthiopiaObjective: To determine potency and safety of the experimental formalin inactivated cell culture based anti-rabies vaccines.Methodology:Mice: 10-16 g weight, 2 weeks age mice with identical sex were used.Inactivation: The viral suspension was thawed and formalin inactivation was done using a concentration of 1:5000 vol/vol andincubated at 37 0 C for 48 h with shaking twice a day.Safety Test: Safety test determines the presence of residual virulent virus and any bacterial contamination in the vaccine.Presences of residual virus were done on mice and any other contamination tested bacteriologically.Potency Test: Potency test determines the degree of protection conferred by the vaccine in immunized mice challenged withchallenge virus strain. This test was performed using National Institutes of Health (NIH) test.Immunization: Mice were immunized at day 0 and 7 with five different concentrations for test vaccine and four differentconcentrations for control vaccine, 16 mice in each dilution. The control vaccine used was Vero Rab vaccine which wasproduced by Sanofi Pasteur.Challenge Test: Standard CVS strain from CDC was used for challenging. Mice were challenged on 14 th day of immunizationwith challenge virus strain (CVS-11) of 25 MLD 50/0.03 ml. The mice were observed for 14 days.Result: Potency of our test vaccine calculated using NIH test was 8.32 IU for ERA and 2.5 IU for PV results were obtained.Conclusion: Based on the result it can be concluded that, both of our vaccines have higher potency than required for single doseof anti rabies vaccine. Therefore these can be diluted to standard vaccine potency and be used for animal immunization.agagurmu@yahoo.comJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 118
Afshineh Latifynia et al., J <strong>Vaccines</strong> Vaccin <strong>2013</strong>, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0183 rd International Conference on<strong>Vaccines</strong> & VaccinationJuly 29-31, <strong>2013</strong> Embassy Suites Las Vegas, NV, USAA comparison of effect of new formulation antigen on Th1 & Th2 cytokine profiles, and,their relationship with spleen' white pulp size expansion in balb/c mice, post challengingwith Leishmania majorAfshineh Latifynia, A. Khamesipour, Gharagozlou M. J., Mohebali M., Hajaran H. and N. KhansariTehran University of Medical Sciences, Islamic Republic of IranHuman leishmaniasis is distributed worldwide, but mainly in the tropics and subtropics, with a prevalence of 12 millioncases and an approximately incidence of 0.5 million cases of VL and 1.5 million cases of cutaneous leishmaniasis (CL).Leishmania parasites are vector-born protozoan pathogens found in tropical and subtropical regions of both the old and newworld. The disease in human can be divided into cutaneous, visceral, and mucosal syndromes. The aim of this study was toconduct more experiments over our previous new formulation modify leishmania major antigen that had satisfactory results,before.In this study we have made preliminarily new vaccine with the same methodology again and selected two injection doses(100 & 200 μg/0.1ml), three injection groups: Leishmania plus BCG (LB), Leishmania plus new adjuvant (Teucrium Polium)[LT],leishmania plus BCG and Teucrium Polium (LBT),and one susceptible mice(Balb/c) and measure two type cytokines: Th1(IFN-γ,IL-12) and Th2(IL-4,IL-10) and expansion of white pulp size after challenge with live leishmania. Results show that both dosesover LBT group have highest IL-12, lowest IL-10 and highest increasing in spleen’s white pulp size, whether; other two groupshave lower IL-12, higher IL-10 and lowest increasing in spleen’s white pulp size in susceptible mice. When all of the three groupsand two genius Balb/c mice (male/female), considered, and without consideration injection dose, the largest white pulp size wereseen in female Balb/c LBT group, and smallest white pulp size were seen in male Balb/c LT group).Conclusion: Our study show that in Balb/c mice, best injection group that produced highest IL-12 and lowest IL-10 and highestincreasing in spleen’s white pulp size, is LBT group, which have significant differences with others. This finding show that,adjuvant BCG both Teucrium have synergic effect with together.BiographyAfshineh Latifynia has completed her M.Sc. at the age 33 years from Tehran University and is studying M.Phil. courses of her Ph.D. in PrimaryImmunodefi ciency Research Center in Faculty of Medicine, Tehran University of Medical Sciences (TUMS). She has published more than 10 papersin PubMed, Scopus, and one of them had choice as ten top articles in 2010, and top twenty in 2011, and another one, as twenty fi ve hot tops articlein 2010. She has three articles under review and also has two articles in the pre submit step. She is teacher and researcher in the Department ofImmunology, Faculty of Medicine, TUMS, and her Ph.D. thesis is about MSMD (Mendelian Susceptibility Mycobacterium Disease).alatifynia@sina.tums.ac.irJ <strong>Vaccines</strong> Vaccin <strong>2013</strong>ISSN: 2157-7560, JVV an open access journal<strong>Vaccines</strong>-<strong>2013</strong>July 29-31, <strong>2013</strong>Volume 4 Issue 5Page 119
- Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
- Page 3 and 4:
Medical SciencesISSNAddiction Resea
- Page 5 and 6:
Impact Factors (IF) and Index Coper
- Page 7 and 8:
111 th OMICS Group Conference3 rd I
- Page 9 and 10:
Journal of Clinical & Cellular Immu
- Page 11 and 12:
111 th OMICS Group Conference3 rd I
- Page 13 and 14:
111 th OMICS Group Conference3 rd I
- Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
- Page 17 and 18:
Immunology Summit-2013OMICS Group i
- Page 19 and 20:
Probiotics-2013OMICS Group is organ
- Page 21 and 22:
Virology-2013OMICS Group is organiz
- Page 23 and 24:
111 th OMICS Group Conference3 rd I
- Page 25 and 26:
Because of heightened awareness of
- Page 27 and 28:
111 th OMICS Group Conference3 rd I
- Page 29 and 30:
111 th OMICS Group Conference3 rd I
- Page 31 and 32:
111 th OMICS Group Conference3 rd I
- Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
- Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
- Page 37 and 38:
111 th OMICS Group Conference3 rd I
- Page 39 and 40:
Robert E. Sievers et al., J Vaccine
- Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
- Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
- Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
- Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
- Page 49 and 50:
Track 33: Novel Approaches in Desig
- Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
- Page 53 and 54:
Benjamin Petsch, J Vaccines Vaccin
- Page 55 and 56:
A. Bennett Jenson et al., J Vaccine
- Page 57 and 58:
Milan Raska et al., J Vaccines Vacc
- Page 59 and 60:
Muhammad Ali A. Shah et al., J Vacc
- Page 61 and 62:
Track 44: Vaccines against Infectio
- Page 63 and 64:
Haval Shirwan, J Vaccines Vaccin 20
- Page 65 and 66:
Rainer Fischer, J Vaccines Vaccin 2
- Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
- Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
- Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
- Page 73 and 74: Young Research ForumSession ChairPe
- Page 75 and 76: Humberto Hernandez et al., J Vaccin
- Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
- Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
- Page 81 and 82: Kaissar Tabynov et al., J Vaccines
- Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
- Page 85 and 86: Track 5 & 95: Manufacturing, Produc
- Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
- Page 89 and 90: Obradovic Zarema et al., J Vaccines
- Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
- Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
- Page 95 and 96: 111 th OMICS Group Conference3 rd I
- Page 97 and 98: Regina Heidenreich et al., J Vaccin
- Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
- Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
- Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
- Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
- Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
- Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
- Page 111 and 112: Byung Chul Kim et al., J Vaccines V
- Page 113 and 114: STS. Chitradevi et al., J Vaccines
- Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
- Page 117: 111 th OMICS Group Conference3 rd I
- Page 121 and 122: Hemanta Koley et al., J Vaccines Va
- Page 123 and 124: Aleksandar Masic et al., J Vaccines
- Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
- Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
- Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
- Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
- Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
- Page 135 and 136: Mathan Periasamy et al., J Vaccines
- Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
- Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
- Page 141 and 142: 111 th OMICS Group Conference3 rd I
- Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
- Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
- Page 147 and 148: Belachew Etana et al., J Vaccines V
- Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
- Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
- Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
- Page 155 and 156: Sandeepkumar R. Chauhan et al., J V
- Page 157 and 158: Veronica Rainone et al., J Vaccines
- Page 159 and 160: Page 159
- Page 161 and 162: Previous111 th OMICS Group Conferen
- Page 163 and 164: PreviousWorld Congress and Expo onB